Business
AB Science reports its revenues for the year 2024 and provides an update on its activities
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2024 AND THE KEY EVENTS OF THE PERIOD Financial and corporate situation Operating deficit of 6,1 million euros as of December 31, 2024, down 55% compared to December 31, 2023Cash position of 8,0 million euros as of December 31, 2024 Clinical development Masitinib platform: Update on the development of masitinib in progressive forms of multiple sclerosis following the ECTRIMS 2024 conferencePositive results from the ph
About this update from Ab Science Sa
[{"type":"image","alt":"AB Science","displaySize":"","headline":null,"caption":"AB Science","className":"","disableSlideshowImg":false,"size":{"original":{"width":156,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AW2UM4sIueJ.X0XSJNjHhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2","width":156,"height":160}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2024 AND THE KEY EVENTS OF THE PERIOD","length":102,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Financial and corporate situation","length":33,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Operating deficit of 6,1 million euros as of December 31, 2024, down 55% compared to December 31, 2023","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash position of 8,0 million euros as of December 31, 2024","length":58,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":160,"olType":false}]},{"val":[{"type":"text","content":"Clinical development","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Masitinib platform:","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Update on the development of masitinib in progressive forms of multiple sclerosis following the ECTRIMS 2024 conference","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"Positive results from the phase 2 study of masitinib in Covid-19","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Update on the EMA's decision concerning the application for conditional marketing authorization for masitinib in the treatment of amyotrophic lateral sclerosis Health Canada re-examination procedure","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"Update on the confirmatory programme for neurodegenerative diseases","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthening the intellectual property of masitinib in mastocytosis","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthening the intellectual property of masitinib in sickle...